Indication
Clear Cell Renal Cell Carcinoma
24 clinical trials
32 products
7 drugs
Clinical trial
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA ExpressionStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-2100 in Patients With Recurrent Advanced or Metastatic Clear-cell Renal Cell Carcinoma (ccRCC)Status: Recruiting, Estimated PCD: 2025-02-26
Product
AB-2100Product
REGN5678Product
CemiplimabClinical trial
An Open Label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell CarcinomaStatus: Completed, Estimated PCD: 2023-08-30
Product
PT2385Clinical trial
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of a Single Dose of Gallium [68Ga]-NYM005 Injection Prepared by Kit for the Preparation of the 68Ga-NYM005 Injection in Patients With Metastatic Clear Cell Renal Carcinoma.Status: Recruiting, Estimated PCD: 2024-12-01
Product
KO-2806Product
CabozantinibProduct
AdagrasibClinical trial
Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-01-01
Product
68Ga-NYM005Clinical trial
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-07-31
Product
AtezolizumabProduct
RO7502175Clinical trial
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-08-01
Product
ALLO-647Product
CyclophosphamideProduct
ALLO-316Product
FludarabineClinical trial
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2020-04-24
Product
CB-839Product
NivolumabClinical trial
A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-08-31
Product
BelzutifanClinical trial
Phase Ib/ll Clinical Study to Evaluate Safety and Dosing of Humanised Monoclonal Antibody CA9hu-1 to Human Carbonic Anhydrase IX in Patients With Advanced Solid TumoursStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Product
CA9hu-1Clinical trial
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma: a Single-center, Prospective, Phase II Umbrella Clinical StudyStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase II Study of Lenvatinib Plus Everolimus Versus Cabozantinib in Patients With Metastatic Renal Cell Carcinoma That Progressed on A PD-1/PD-L1 Checkpoint InhibitorStatus: Recruiting, Estimated PCD: 2025-10-25
Product
EverolimusProduct
LenvatinibClinical trial
Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)Status: Recruiting, Estimated PCD: 2025-07-01
Product
IpilimumabClinical trial
A Phase 1/2 Open-label Study of Pembrolizumab Combined With PNT-2002 Radioligand Therapy in Patients With Metastatic Renal Cell CarcinomaStatus: Not yet recruiting, Estimated PCD: 2030-07-01
Product
PembrolizumabProduct
177Lu-PNT2002Product
(F-18)-DCFPyLClinical trial
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-08-30
Drug
AdavosertibClinical trial
Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Cabozantinib/Nivolumab for Patients With Metastatic Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-10-25
Clinical trial
A Multicentric, Single Arm, Open-label, Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal CancerStatus: Recruiting, Estimated PCD: 2026-04-01
Product
177Lu-PSMA-1Clinical trial
A Phase II Trial of Sitravatinib Plus Nivolumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma Who Progressed on Prior Treatment Acronym: SNAPI (Sitravatinib and Nivolumab After Prior Immunotherapy)Status: Active (not recruiting), Estimated PCD: 2025-01-31
Drug
SitravatinibClinical trial
A Phase II Study of Perioperative Pembrolizumab-Based Therapy in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Prior to Cytoreductive Nephrectomy or MetastasectomyStatus: Recruiting, Estimated PCD: 2024-09-01
Product
AxitinibDrug
mFOLFOX6Clinical trial
A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell CarcinomaStatus: Terminated, Estimated PCD: 2022-07-26
Drug
interleukin-2Clinical trial
Avelumab, Palbociclib and Axitinib in in Treatment Naive Metastatic Clear Cell Renal Cell Carcinoma.Status: Withdrawn, Estimated PCD: 2026-08-31
Product
PalbociclibProduct
AvelumabClinical trial
Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)Status: Recruiting, Estimated PCD: 2033-07-01
Product
Active ComparatorClinical trial
An Open-Label, Phase I, Dose-Finding Study of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Advanced Stage Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-10-19
Product
CBM588Drug
LurbinectedinDrug
T-VECClinical trial
DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) CarcinomasStatus: Recruiting, Estimated PCD: 2026-12-31
Drug
Valemetostat